脊柱肌肉缩的药物治疗患者的骨矿物质密度变化
Abdelrahman Osman1, Halley Wasserman2, Paul S Horn3
1University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45220, USA.
Neuromuscular disorders : NMD
|February 19, 2025
概括
脊柱肌缩 (SMA) 疗法对骨健康有前途,特别是在婴儿中. 虽然并没有完全使所有患者的骨密度正常化,但治疗显著降低了骨折频率.
科学领域:
- 儿科神经学 儿科神经学
- 骨的新陈代谢 骨的新陈代谢
- 遗传神经肌肉疾病 遗传神经肌肉疾病
背景情况:
- 脊椎肌肉缩 (SMA) 与行走和运动能力的减少有关,增加了骨健康状况下降的风险.
- 最近的进展包括FDA批准的SMA治疗方法,需要评估它们对骨完整性的影响.
研究的目的:
- 分析新型脊髓肌缩治疗对患者骨矿物质密度 (BMD) 的影响.
- 为了评估在不同患者队列中治疗干预后的骨和骨折发生率的变化.
主要方法:
- 双能X射线吸收计 (DXA) 扫描数据的回顾性分析,来自27名患有SMA类型1,2或3的患者.
- 患者被分为两组:那些治疗前和治疗后DXA扫描 (老年队列) 和那些仅治疗后扫描 (婴儿治疗队列) 的患者.
- 骨矿物质密度 (BMD) Z-score和骨折频率在治疗开始前后进行评估.
主要成果:
- 在较老的队列中 (治疗前和治疗后的DXA),SMA药物治疗没有使先前存在的低骨矿物质密度正常化 (BMD Z-score > -2).
- 在婴儿期接受治疗的队列中,与老年队列相比,患者的正常骨矿物质密度发生率更高.
- 治疗后骨折的频率显著下降,从52%降至14%的患者 (p = 0.0584).
结论:
- 目前的脊椎肌肉缩疗法可能无法完全逆转已建立的低骨密度,但在年轻患者中显示出潜力.
- 对SMA的治疗干预似乎减少了骨折的发生率,这表明它对骨健康产生了积极影响.
- 需要进一步的研究,以优化脊髓肌缩症患者接受新型治疗的骨健康管理.
相关概念视频
Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Bone Remodeling
38.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
34
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
34


